Haisam Al Khouri, MD
Psychiatry · Oklahoma City, OKNPI 1558318030
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 544 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 20.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,114 and has fallen 57.9% since, to $890 in 2025. Among psychiatry clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 544 payments — averaging $17.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- AbbVie$1K
- Johnson & Johnson$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$884
- Vanda Pharmaceuticals Inc.$547
- plus $3K from 21 others
What the payments were for
- Food & beverage$9,33998%
- Education$1952%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 129 | $1,918 |
| AbbVie(2 entities) | 79 | $1,240 |
| Johnson & Johnson | 58 | $1,234 |
| Otsuka America Pharmaceutical, Inc. | 68 | $1,130 |
| Teva Pharmaceuticals USA, Inc. | 49 | $884 |
| Vanda Pharmaceuticals Inc. | 24 | $547 |
| Sunovion Pharmaceuticals Inc. | 18 | $338 |
| Neurocrine Biosciences, Inc. | 34 | $272 |
| E.r. Squibb & Sons, L.L.C. | 2 | $244 |
| Indivior Inc. | 9 | $230 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $208 |
| Alkermes, Inc. | 5 | $183 |
| Bausch Health US, LLC | 8 | $180 |
| Shire North American Group Inc | 10 | $167 |
| Lundbeck LLC | 7 | $120 |
| Avanir Pharmaceuticals, Inc. | 7 | $119 |
| Neuronetics, Inc. | 2 | $91 |
| Supernus Pharmaceuticals, Inc. | 5 | $86 |
| Noven Therapeutics, LLC | 4 | $73 |
| Ironshore Pharmaceuticals Inc. | 3 | $61 |
| Almatica Pharma LLC | 3 | $58 |
| Eisai Inc. | 2 | $38 |
| Adlon Therapeutics L.p. | 2 | $34 |
| Jazz Pharmaceuticals Inc. | 2 | $27 |
| Harmony Biosciences LLC | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Vertical Pharmaceuticals, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVEGA SUSTENNA$477
- LYBALVI$469
- COBENFY$244
- CAPLYTA$219
- INVEGA TRINZA$217
- VRAYLAR$113
- REXULTI$109
- PERSERIS$101
How this compares
$9,535 in reported general payments places this provider in the 90th percentile of 328 psychiatry providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 119 | $1,066,254 |
| IngrezzaValbenazine Tosylate | 21 | $163,343 |
| Invega TrinzaPaliperidone Palmitate | 16 | $143,300 |
| Invega SustennaPaliperidone Palmitate | 46 | $126,257 |
| VraylarCariprazine Hcl | 68 | $96,406 |
| FanaptIloperidone | 15 | $46,522 |
| Abilify MaintenaAripiprazole | 15 | $40,410 |
| RexultiBrexpiprazole | 23 | $33,692 |
| VivitrolNaltrexone Microspheres | 13 | $21,296 |
| Lurasidone Hcl | 68 | $16,872 |
| Chlorpromazine Hcl | 25 | $10,059 |
| BelsomraSuvorexant | 21 | $8,491 |
| Olanzapine OdtOlanzapine | 106 | $8,308 |
| TrintellixVortioxetine Hydrobromide | 16 | $7,723 |
| AdderallDextroamphetamine/Amphetamine | 14 | $7,427 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $884 | $1,066,254119 claims |
| Johnson & JohnsonInvega Trinza, Invega Sustenna | $1,234 | $269,55762 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $272 | $163,34321 claims |
| AbbVieVraylar, Fetzima | $1,240 | $101,95779 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $1,130 | $74,10138 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $547 | $46,52215 claims |
| Alkermes, Inc.Vivitrol | $183 | $21,29613 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Adderall | $208 | $15,15030 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 328 psychiatry providers in Oklahoma.
Other psychiatry in Oklahoma City
- Willis HollowayOklahoma City$92K
- Adonis Al BotrosOklahoma City$73K
- Marvin PeytonOklahoma City$60K
- Josephine DeguzmanOklahoma City$38K
- Patrick HornOklahoma City$8K
- Shreekuma VinekarOklahoma City$7K
- Relindis TitaOklahoma City$6K
- Janita ArdisOklahoma City$6K
- Fiona LiOklahoma City$5K
- Ahsan KhanOklahoma City$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.